Zydus Cadila gets USFDA nod to market HIV infection treatment tablets
The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
New Delhi: Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market generic Emtricitabine and Tenofovir Disoproxil Fumarate tablets used for treatment of HIV infection.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, Zydus Cadila said in a statement.
The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad, it added.
The drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in one’s body so that the immune system can work better, Zydus Cadila said.
The group now has 319 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
Shares of Cadila Healthcare, the listed entity of Zydus group were trading at Rs 639.95 per scrip on BSE, up 0.18 per cent from its previous close.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
